491 related articles for article (PubMed ID: 28625204)
1. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Potkin SG; Risinger R; Du Y; Zummo J; Bose A; Silverman B; Stankovic S; Ehrich E
Schizophr Res; 2017 Dec; 190():115-120. PubMed ID: 28342578
[TBL] [Abstract][Full Text] [Related]
4. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
[TBL] [Abstract][Full Text] [Related]
5. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ
Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Nasrallah HA; Weiden PJ; Walling DP; Du Y; Yao B; Yagoda S; Claxton A
BMC Psychiatry; 2021 Oct; 21(1):492. PubMed ID: 34625041
[TBL] [Abstract][Full Text] [Related]
8. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics.
Peters-Strickland T; Zhao C; Perry PP; Eramo A; Salzman PM; McQuade RD; Johnson BR; Sanchez R
CNS Spectr; 2016 Dec; 21(6):460-465. PubMed ID: 27531181
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
[TBL] [Abstract][Full Text] [Related]
10. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Lauriello J; Claxton A; Du Y; Weiden PJ
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32841554
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
12. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
McEvoy JP; Risinger R; Mykhnyak S; Du Y; Liu CC; Stanford AD; Weiden PJ
J Clin Psychiatry; 2017; 78(8):1103-1109. PubMed ID: 28937706
[TBL] [Abstract][Full Text] [Related]
13. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Weiden PJ; Du Y; Liu CC; Stanford AD
CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
[TBL] [Abstract][Full Text] [Related]
18. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
